Given the easy and cost-effective production and the auspicious imaging characteristics of peptide-based radiotracers, including rapid elimination, fast penetration into tissues, and negligible antigenicity, NGR-based radiopharmaceuticals are considered groundbreaking in the non-invasive, early identification of APN/CD13 positive tumours [22,26,27,28,29]. This evidence concerns the gene ANPEP and neoplasm.